[go: up one dir, main page]

AR020021A1 - Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal - Google Patents

Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal

Info

Publication number
AR020021A1
AR020021A1 ARP990106217A ARP990106217A AR020021A1 AR 020021 A1 AR020021 A1 AR 020021A1 AR P990106217 A ARP990106217 A AR P990106217A AR P990106217 A ARP990106217 A AR P990106217A AR 020021 A1 AR020021 A1 AR 020021A1
Authority
AR
Argentina
Prior art keywords
senal
composition
cancer treatment
essential oils
transduction modulators
Prior art date
Application number
ARP990106217A
Other languages
English (en)
Original Assignee
Ecosmart Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecosmart Technologies Inc filed Critical Ecosmart Technologies Inc
Publication of AR020021A1 publication Critical patent/AR020021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas que contienen compuestos de aceites esenciales de plantas, naturales o sintéticos, o mezclas o derivados de los mismos, con unoo más moduladores de transduccion de senal, para la prevencion y el tratamiento de cáncer.
ARP990106217A 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal AR020021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11127198P 1998-12-07 1998-12-07

Publications (1)

Publication Number Publication Date
AR020021A1 true AR020021A1 (es) 2002-03-27

Family

ID=22337523

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990106217A AR020021A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal
ARP990106216A AR020020A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
ARP990106215A AR020019A1 (es) 1998-12-07 1999-12-07 Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP990106216A AR020020A1 (es) 1998-12-07 1999-12-07 Composicion para el tratamiento de cancer y metodo usando moduladores de transduccion de senal y aceites esenciales de plantas naturales como sinergistas para tratamientos convencionales
ARP990106215A AR020019A1 (es) 1998-12-07 1999-12-07 Composicion farmaceutica para la prevencion o el tratamiento de cancer de mama

Country Status (24)

Country Link
US (8) US20030017215A1 (es)
EP (3) EP1137426B1 (es)
JP (3) JP2002531511A (es)
KR (1) KR20010080692A (es)
CN (1) CN100448454C (es)
AR (3) AR020021A1 (es)
AT (1) ATE307601T1 (es)
AU (3) AU2167000A (es)
BR (1) BR9916879A (es)
CA (3) CA2353476A1 (es)
CZ (1) CZ20011979A3 (es)
DE (1) DE69928000T2 (es)
ES (1) ES2247858T3 (es)
HU (1) HUP0104674A3 (es)
ID (1) ID29393A (es)
IL (1) IL143488A0 (es)
MX (3) MXPA01005641A (es)
NO (1) NO20012774D0 (es)
NZ (1) NZ527850A (es)
PL (1) PL349028A1 (es)
RU (1) RU2252772C2 (es)
TR (1) TR200101481T2 (es)
WO (3) WO2000033856A1 (es)
ZA (1) ZA200104611B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100448454C (zh) * 1998-12-07 2009-01-07 艾科斯迈特技术公司 用于癌症治疗的天然植物精油组合物及方法
DE10113513A1 (de) * 2001-03-20 2002-10-02 Medinnova Ges Med Innovationen Kombinationspräparat zur Prophylaxe und/oder Therapie von Nervenzell- und/oder Gliazellschäden durch ein neues Behandlungsverfahren
US7186735B2 (en) * 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
EP2387882A3 (en) * 2002-08-12 2012-10-31 Lonza Inc. Antimicrobial compositions comprising cinnamaldehyde
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
DE10259619A1 (de) * 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
MD2231C2 (ro) * 2003-03-05 2004-02-29 Ион КАЛМЫК Compozitie pentru tratamentul patologiilor oncologice
US7622269B2 (en) 2004-03-19 2009-11-24 Tyratech, Inc. Methods of screening tyramine- and octopamine-expressing cells for compounds and compositions having potential insect control activity
JP2007502860A (ja) 2003-04-24 2007-02-15 ヴァンダービルト ユニバースィティ 昆虫を防除するための組成物及び方法
US20060263403A1 (en) * 2003-04-24 2006-11-23 Essam Enan Compositions and methods for controlling insects involving the tyramine receptor
ES2476902T5 (es) * 2003-07-02 2018-04-03 Genentech, Inc. Compuestos activadores de TRP-P8 y métodos de tratamiento terapéuticos
DE10341933A1 (de) * 2003-09-11 2005-04-14 Lts Lohmann Therapie-Systeme Ag Medizinische Hautpflaster mit einem Gehalt an ätherischen Ölen zur Behandlung von Erkältungskrankheiten, sowie Verfahren für deren Herstellung
SE0401302D0 (sv) * 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Inhibition of erk-phosphorylation
WO2006120495A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
CN100553628C (zh) 2005-08-25 2009-10-28 中国人民解放军军事医学科学院放射与辐射医学研究所 2-溴-异香兰素在制备抗癌和/或辐射、化疗增敏药物中的应用
MX2008016453A (es) 2006-06-27 2009-05-15 Tyratech Inc Composiciones y metodos para tratar infecciones parasitas.
EP2048944A4 (en) * 2006-07-17 2012-06-27 Tyratech Inc COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS
EP2077724A2 (en) * 2007-01-16 2009-07-15 Tyratech, Inc. Pest control compositions and methods
JP2011021013A (ja) * 2009-06-19 2011-02-03 Ube Industries Ltd オキシル基を有する芳香族メチルアルコール化合物の製造方法
CA2801143C (en) 2009-09-24 2017-09-26 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
US8003393B1 (en) * 2010-02-09 2011-08-23 Panasonic Corporation Method for determining whether or not a mammal is affected with a lung cancer
WO2012006563A2 (en) 2010-07-08 2012-01-12 The Administrators Of The Tulane Educational Fund Novel daidzein analogs as treatment for cancer
FR2967055B1 (fr) * 2010-11-08 2012-12-21 Biochimie Appliquee Solabia Compositions cosmetiques a base d'esters de piperonyle et leur utilisation en sosmetique en tant qu'anti-vieillissement cutane et agent depigmentant
EP2648681B1 (en) 2010-12-07 2015-01-07 Unilever N.V. An oral care composition
EP2714021A1 (en) * 2011-02-02 2014-04-09 Max Reynolds Composition of monoterpenoids having bactericidal properties
US8952067B2 (en) * 2011-06-20 2015-02-10 Atheronova Operations, Inc. Subcutaneous fat reduction
IN2014MN00808A (es) 2011-11-03 2015-09-04 Unilever Plc
KR101357395B1 (ko) 2012-08-06 2014-02-05 영남대학교 산학협력단 신규한 테트라졸로 하이드라존 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학 조성물
WO2015102448A1 (ko) * 2014-01-03 2015-07-09 전북대학교 산학협력단 신남알데히드 및 퀴논 메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
KR101688887B1 (ko) * 2014-01-03 2016-12-23 전북대학교산학협력단 신남알데히드 및 퀴논 메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
WO2015140002A1 (en) * 2014-03-20 2015-09-24 Nestec S.A. Methods and compositions for using cinnamaldehyde and zinc for weight management
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106687A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
DE202015106125U1 (de) * 2015-10-23 2016-10-27 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Monoterpenhaltige Zusammensetzung zur Behandlung von Tumor- und/oder Krebserkrankungen
CN105294465A (zh) * 2015-12-08 2016-02-03 天津医科大学 一种抗乳腺癌转移作用的手性紫罗兰酮生物碱衍生物及医药用途
CN105559074B (zh) * 2016-02-03 2019-02-12 华南农业大学 一种茶叶挥发性精油在制备防癌保健品或抗癌药物中的应用
KR101798203B1 (ko) 2016-09-23 2017-11-15 전북대학교 산학협력단 산성 pH 및 에스테라아제에 의해 신남알데히드 및 퀴논메티드를 동시에 생성하는 혼성 항암 전구약물 및 이의 제조방법
RU2020135149A (ru) 2018-04-06 2022-05-06 Уцар Хелс ГМбХ Лечение рака производными гуанидиния
CN109112106B (zh) * 2018-09-07 2022-01-04 广州长峰生物技术有限公司 人原代肝癌组织的体外模型的建立方法
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022069013A1 (fr) * 2020-10-04 2022-04-07 Omar Bencherguia Composition médicamenteuse pour le traitement et la prévention du covid-19 et autres infections et affections nouvelles applications de l'alpha-acetoxytoluène, l'alcool benzylique et les groupes benzyle dans la lutte contre la pandémie covid-19 et autres infections et affections
CN119488512A (zh) * 2024-12-18 2025-02-21 澳门大学 肉桂醇及其衍生物在制备预防或治疗肿瘤的药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS57106697A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
FR2557452B1 (fr) * 1983-12-28 1986-08-14 Roussel Uclaf Nouvelles compositions pour les soins de la peau renfermant de l'huile d'onagre et des traits tissulaires de rate
DE3515253C1 (de) * 1985-04-27 1986-06-19 Werner 6780 Pirmasens Walter Verwendung von isopropanolischen Lösungen von Diphenyl als topisches Arzneimittel
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
AT393221B (de) * 1988-02-03 1991-09-10 Leopold Pharma Gmbh Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken
DE3826846A1 (de) * 1988-08-06 1990-02-08 Goedecke Ag Alkoxy-4(1h)-pyridon-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE3829200A1 (de) * 1988-08-29 1990-03-01 Kaempgen Dieter Dr Phil Wirkstoffe gegen die immunschwaeche-krankheit aids
JP2746453B2 (ja) * 1990-03-13 1998-05-06 鐘紡株式会社 活性酸素消去剤
EP0448029B1 (en) 1990-03-23 1995-12-20 Nippon Kayaku Kabushiki Kaisha Novel pharmaceutical uses of forskolin derivatives
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
FR2683454B1 (fr) 1991-11-13 1995-06-09 Pf Medicament Composition pharmaceutique bactericide.
JPH07500114A (ja) * 1991-12-13 1995-01-05 ジー．ディー．サール　アンド　カンパニー 経皮吸収性アジドチミジン
DE69304595T2 (de) * 1992-04-29 1997-01-23 Nordica Spa Bremsvorrichtung an Rollschuh
NZ252051A (en) * 1992-05-19 1996-10-28 Graham Edmund Kelly Health supplement comprising a phyto-oestrogen selected from genistein, daidzein, biochanin and/or formononetin
FR2697133B1 (fr) * 1992-10-28 1995-01-13 Transbiotech Composition biocide et/ou biostatique et ses applications.
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
US5387584A (en) * 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
JP3263481B2 (ja) 1993-05-19 2002-03-04 三洋電機株式会社 半導体装置および半導体装置の製造方法
FR2706771A1 (en) * 1993-06-21 1994-12-30 Pelletier Jacques Formula for the treatment of certain cancers.
RU2088245C1 (ru) * 1993-07-07 1997-08-27 Научно-исследовательский институт онкологии им.проф.Н.Н.Петрова Способ профилактики повышенного онкологического риска
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
RU2102947C1 (ru) * 1994-01-12 1998-01-27 Любовь Сергеевна Кондаурова Средство для лечения заболеваний переднего отрезка глаза
RU2088247C1 (ru) * 1994-01-31 1997-08-27 Фонд содействия исследованиям и инициативам граждан по оздоровлению человека и среды им.Караваева В.В. Способ повышения эффективности лучевой терапии
US5626854A (en) 1994-03-17 1997-05-06 Kao Corporation Bath composition
US5911995A (en) * 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
HUP0002049A2 (hu) * 1997-03-04 2000-10-28 Wisconsin Alumni Research Foundation Tumornövekedés megakadályozására szolgáló eljárás izoprenoidok és sztatinok kombinációk alkalmazásával
WO1998048790A1 (en) 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
ES2339196T3 (es) * 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
CN1286625A (zh) * 1998-03-20 2001-03-07 宝洁公司 释放香味的组合物
AT407821B (de) * 1998-03-24 2001-06-25 Franz Dr Stueckler Mittel auf der basis von naturstoffen
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
AU1041400A (en) * 1998-10-23 2000-05-15 Dieter Ebert Composition containing eugenol and polyphenols and use of such a composition forwound healing
KR100312622B1 (ko) * 1998-11-03 2002-02-28 김송배 생약을주성분으로한안정화된항암제조성물및그제조방법
CN100448454C (zh) * 1998-12-07 2009-01-07 艾科斯迈特技术公司 用于癌症治疗的天然植物精油组合物及方法
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Also Published As

Publication number Publication date
EP1137427A1 (en) 2001-10-04
TR200101481T2 (tr) 2001-09-21
US7291650B2 (en) 2007-11-06
HUP0104674A2 (en) 2002-06-29
CN1329498A (zh) 2002-01-02
US20020182268A1 (en) 2002-12-05
JP2002531511A (ja) 2002-09-24
DE69928000D1 (de) 2005-12-01
JP2002531512A (ja) 2002-09-24
PL349028A1 (en) 2002-07-01
ID29393A (id) 2001-08-30
NZ527850A (en) 2004-07-30
WO2000033857A1 (en) 2000-06-15
EP1137426A1 (en) 2001-10-04
US20030108622A1 (en) 2003-06-12
US7008649B2 (en) 2006-03-07
WO2000033857A9 (en) 2001-12-13
NO20012774L (no) 2001-06-06
CZ20011979A3 (cs) 2001-10-17
WO2000033856A1 (en) 2000-06-15
AR020020A1 (es) 2002-03-27
CA2353516A1 (en) 2000-06-15
US20080015249A1 (en) 2008-01-17
CA2353475A1 (en) 2000-06-15
AU1841900A (en) 2000-06-26
ZA200104611B (en) 2001-12-13
NO20012774D0 (no) 2001-06-06
EP1137425A1 (en) 2001-10-04
CA2353476A1 (en) 2000-06-15
IL143488A0 (en) 2002-04-21
US20030108623A1 (en) 2003-06-12
US20030017218A1 (en) 2003-01-23
ES2247858T3 (es) 2006-03-01
US20030017215A1 (en) 2003-01-23
US20040146595A1 (en) 2004-07-29
WO2000033858A1 (en) 2000-06-15
BR9916879A (pt) 2001-11-06
KR20010080692A (ko) 2001-08-22
US20040156922A1 (en) 2004-08-12
JP2002531513A (ja) 2002-09-24
RU2252772C2 (ru) 2005-05-27
HUP0104674A3 (en) 2003-01-28
AU2167100A (en) 2000-06-26
MXPA01005641A (es) 2003-07-14
MXPA01005598A (es) 2003-07-14
DE69928000T2 (de) 2006-06-08
ATE307601T1 (de) 2005-11-15
MXPA01005545A (es) 2003-07-14
AR020019A1 (es) 2002-03-27
EP1137426B1 (en) 2005-10-26
US6812258B2 (en) 2004-11-02
AU2167000A (en) 2000-06-26
CN100448454C (zh) 2009-01-07

Similar Documents

Publication Publication Date Title
AR020021A1 (es) Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ES2190479T3 (es) Moduladores de rxr selectivos a dimeros y metodos para su uso.
ES2115298T3 (es) Nuevos derivados de 1-fenil-3-dimetil-amino-propano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2165441T3 (es) Inhibidores de calpaina y/o catepsina b oxazolidin sustituidos.
ES2079719T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su utilizacion y agentes que los contienen en calidad de anticoagulantes.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
CU23393A3 (es) Compuestos inhibidores de la raf kinasa y composiciones farmacéuticas que los contienen
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR010346A1 (es) COMPUESTOS DERIVADOS DE BENZOFURANO; SUS USOS, Y COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE.
MX9204844A (es) Derivados de benzodioxano, procedimiento para su preparacion composiciones farmaceuticas que los contienen.
PT991654E (pt) Novos derivados de 2-(iminometil)amino-fenilo sua preparacao sua aplicacao como medicamentos e composicoes farmaceuticas que os contem
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
MX9307232A (es) Arilcicloalquilaminas n,n-disustituidas, sus sales, medicamentos que contiene estos compuestos y su empleo, asi como procedimientos para su preparacion.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
MX9201642A (es) Derivados de amidino fenil alanina, procedimiento para su preparacion, su empleo y agentes que los contienen.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
AR009809A1 (es) Derivados de 10,13,15-trioxatriciclo[9.2.1(9.6)]-pentadecanona, procedimientos para su preparacion y medicamentos que contienen estos compuestos
ES2150461T3 (es) Derivados de amidinofenilalanina, proceso para su preparacion, su empleo y agentes que los contienen como anticoagulantes.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2177811T3 (es) Uso de nitroflavonoides para el tratamiento de la ansiedad.
MX9204395A (es) Derivados de 3-desoxi-manosamina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure